CFS
VNDA icon

CGC Financial Services’s Vanda Pharmaceuticals VNDA Stock Holding History

CGC Financial Services’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306 Hold
50
– – ﹤0.01% 327
2026
Q1 		$346 Hold
50
– – ﹤0.01% 320
2025
Q4 		$441 Hold
50
– – ﹤0.01% 323
2025
Q3 		$250 Hold
50
– – ﹤0.01% 331
2025
Q2 		$236 Hold
50
– – ﹤0.01% 321
2025
Q1 		$230 Hold
50
– – ﹤0.01% 319
2024
Q4 		$240 Hold
50
– – ﹤0.01% 330
2024
Q3 		$235 Hold
50
– – ﹤0.01% 328
2024
Q2 		$283 Hold
50
– – ﹤0.01% 328
2024
Q1 		$206 Hold
50
– – ﹤0.01% 341
2023
Q4 		$211 Hold
50
– – ﹤0.01% 354
2023
Q3 		$216 Hold
50
– – ﹤0.01% 314
2023
Q2 		$330 Buy
+50
New +$321 ﹤0.01% 333

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CGC Financial Services's VNDA Position: Q2 2026 in Review

CGC Financial Services held its Vanda Pharmaceuticals (VNDA) position steady in Q2 2026 at 50 shares worth $306. The position accounts for ﹤0.01% of the portfolio, ranked #327.

CGC Financial Services first reported a position in VNDA in Q2 2023 and has held it in 13 quarters since. The position peaked at $441 in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • CGC Financial Services held 50 shares of Vanda Pharmaceuticals worth $306 as of Q2 2026.
  • CGC Financial Services left its Vanda Pharmaceuticals share count unchanged in Q2 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of CGC Financial Services's portfolio in Q2 2026, its #327 holding.
  • CGC Financial Services first reported a position in Vanda Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • CGC Financial Services's Vanda Pharmaceuticals position peaked at $441 in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on CGC Financial Services's 13F filing for Q2 2026, filed 13 Jul 2026.